A new class of drug slows growth of castration-resistant prostate cancer cellsJanuary 29, 2016
A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina (MUSC) and others.
Christina Voelkel-Johnson, Ph.D., Associate Professor of Microbiology and Immunology at MUSC, led the study, which was funded by a pilot grant from MUSC Hollings Cancer Center. Co-authors include Charles D. Smith, Ph.D., who developed the compound and led an earlier phase 1 trial at MUSC Hollings Cancer Center; MUSC Health oncologist Michael Lilly, M.D., a prostate cancer specialist; and Richard Drake, Ph.D., director of the Proteomics Core at MUSC, who has developed techniques to use MALDI imaging mass spectrometry to measure sphingolipid levels.
Sphingosine kinase inhibitors are a new category of drugs that reduce the generation of sphingosine-1-phosphate. This lipid signaling molecule promotes cancer cell growth and survival, thereby supporting the development of resistance to chemotherapy and radiation by cancer cells.
The study reported in Molecular Cancer Therapeutics showed that the compound YELIVA™ (ABC294640; RedHill Biopharma Ltd.; Tel Aviv, Israel) slowed prostate cancer cell proliferation by inhibiting sphingosine kinase 2, but also that it did something unexpected. "By inhibiting a second sphingolipid enzyme (DEGS), the compound increases levels of another class of lipids -- dihydroceramides -- which may contribute to the growth suppressive effects of the drug," says Voelkel-Johnson.
This study is the first to show activity for this compound against DEGS and to potentially link inhibition of DEGS to slowing the growth of castration-resistant prostate cancer cells. Treatment with YELIVA™ (ABC294640) increased dihydroceramide levels even in the absence of sphingosine kinase 2.
The MUSC team conducted both in vitro and in vivo studies with YELIVA™ (ABC294640) in castration-resistant prostate cancer, relying on the MUSC Lipidomics Shared Resource for measurement of sphingolipid levels and the MUSC Proteomics Center for MALDI imaging mass spectrometry.
In vitro studies conducted with castration-resistant mouse prostate cancer cells (TRAMP-C2) showed that treatment with YELIVA™ (ABC294640) reduced expression of the androgen receptor and the oncogene c-Myc, both important therapeutic targets for prostate cancer. Although many existing prostate cancer therapies target the androgen receptor, none directly target c-Myc.
To test in vivo response, one million TRAMP-C2 cells were injected under the skin of mice with an intact immune system, which were then treated with YELIVA™ (ABC294640) three days later. MALDI imaging mass spectrometry showed the presence of YELIVA™ (ABC294640) within murine tumors and confirmed in vitro findings of increased dihydroceramide levels.
"The significance of these findings is that this compound might be a novel therapeutic for advanced prostate cancer," says Voelkel-Johnson, who believes that combination regimens of YELIVA™ (ABC294640) and focal radiation in this difficult-to-treat patient population deserve further study.
Founded in 1824 in Charleston, The Medical University of South Carolina is the oldest medical school in the South. Today, MUSC continues the tradition of excellence in education, research, and patient care. MUSC educates and trains more than 3,000 students and residents, and has nearly 13,000 employees, including approximately 1,500 faculty members. As the largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $2.2 billion. MUSC operates a 750-bed medical center, which includes a nationally recognized Children's Hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute designated center) Level I Trauma Center, and Institute of Psychiatry. For more information on academic information or clinical services, visit musc.edu. For more information on hospital patient services, visit muschealth.org.
About YELIVA™ (ABC294640)
YELIVA™ (ABC294640), developed by RedHill Biopharma Ltd., is a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with anti-cancer and anti-inflammatory activities, targeting multiple oncology, inflammatory and gastrointestinal indications. By inhibiting the SK2 enzyme, YELIVA™ (ABC294640) blocks the synthesis of sphingosine 1-phosphate (S1P), a lipid signaling molecule that promotes cancer growth and pathological inflammation. YELIVA™ (ABC294640) was originally developed by U.S.-based Apogee Biotechnology Corp. and completed multiple successful pre-clinical studies in oncology, inflammation, GI, and radioprotection models, as well as the ABC-101 Phase Ib clinical study in cancer patients with advanced solid tumors. A Phase I/II clinical study evaluating YELIVA™ (ABC294640) in patients with refractory/relapsed diffuse large B-cell lymphoma (DLBCL) has been initiated in the U.S. A Phase II study with YELIVA™ for the treatment of refractory or relapsed multiple myeloma is planned to be initiated by early 2016 at Duke University. A third Phase II clinical study is planned to evaluate YELIVA™ (ABC294640) as a radioprotectant to prevent mucositis in cancer patients undergoing therapeutic radiotherapy. For more information visit: http://www.RedHillbio.com.
Medical University of South Carolina
Related Prostate Cancer Articles:
The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy (internal radiation) for patients with prostate cancer.
For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track how the tumor progresses.
Moffitt researchers David Basanta, Ph.D., and Conor Lynch, Ph.D., have been awarded a U01 grant to investigate prostate cancer metastasis.
For the first time ever, researchers have differentiated the risks of developing indolent or aggressive prostate cancer in men with a family history of the disease.
A newly discovered connection between two common prostate cancer treatments may soon make prostate cancer cells easier to destroy.
A study from Karolinska Institutet in Sweden shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Primary care providers are put in a difficult position when screening their male patients for prostate cancer -- some guidelines suggest that testing the general population lacks evidence whereas others state that it is appropriate in certain patients.
New research suggests that age, race and family history are the biggest risk factors for a man to develop prostate cancer, although high blood pressure, high cholesterol, vitamin D deficiency, inflammation of prostate, and vasectomy also add to the risk.
Cancer Research UK scientists have for the first time identified that there are five distinct types of prostate cancer and found a way to distinguish between them, according to a landmark study published today in EBioMedicine.
The radiation oncology team at UH Seidman Cancer Center in Cleveland performed the first-ever prostate cancer treatment April 3 using a newly-approved device -- SpaceOAR which enhances the efficacy of radiation treatment by protecting organs surrounding the prostate.
Related Prostate Cancer Reading:
Dr. Patrick Walsh's Guide to Surviving Prostate Cancer
by Patrick C. Walsh (Author), Janet Farrar Worthington (Author)
Each year, more than 230,000 men are diagnosed with prostate cancer, and 30 to 40 percent of patients who are diagnosed will eventually relapse. But the good news is that more men are being cured of this disease than ever before. Now in a revised third edition, this lifesaving guide by Dr. Patrick Walsh and award-winning science writer Janet Farrar Worthington offers a message of hope to every man facing this illness. Prostate cancer is a different disease in every man, which means that the right treatment varies for each man. Readers will discover their risk factors, simple changes that can... View Details
Prostate Cancer: A New Approach to Treatment and Healing
by Dr. Emilia A. Ripoll (Author), Mark B. Saunders (Author)
Prostate Cancer: A New Approach to Treatment and Healing gives readers new access to leading-edge medical information about prostate cancer, by making it simple and easy-to-understand. Essentially, this is a picture book for adults, written in everyday English, with lots of state-of-the-art information to support all the images, flow charts, tables, and diagrams. Each chapter has a patient story, doctor story, and interactive Toolbox section. The book also contains a Spouses Section (because no one goes through a prostate cancer diagnosis alone) and a Digging Deeper section for readers... View Details
You Can Beat Prostate Cancer: And You Don't Need Surgery to Do It
by Robert J. Marckini (Author)
The task of choosing the right prostate cancer treatment is daunting. It is further complicated by conflicting information the patient receives from physicians and the Internet. This book is written by a prostate cancer survivor who now runs an international prostate cancer support group. It's about his journey and the important things he learned along the way. It is the book the author wishes had been available when he was diagnosed 6 years ago. It is intended to provide specific information for men who are at risk or have been recently diagnosed with prostate cancer. All major treatment... View Details
"Prostate Cancer Breakthroughs 2014: New Tests, New Treatments, Better Options: A Step-by-Step Guide to Cutting-Edge Diagnostic Tests and 12 Medically-Proven Treatments
by Jay S. Cohen (Author)
"Vital new information for men diagnosed with prostate cancer!" --George Johnson, Director of the Informed Prostate Cancer Support Group in San Diego, the largest independent group in California
"I have had treatment for prostate cancer and have been thru the mill. If I were going to go through the process again, I would start with Dr Cohen's book." --P.C., independent review at Amazon.com
Updated for 2014, Prostate Cancer Breakthroughs 2014 offers 55 additional pages from the original top-selling book. Also, new information on PSA testing, how to obtain a new targeted biopsy,... View Details
Prostate and Cancer: A Family Guide to Diagnosis, Treatment, and Survival
by Sheldon Marks (Author)
Prostate cancer is one of the most common cancers affecting American men, with over 186,000 new cases diagnosed in the United States annually; 1 in 6 men will be diagnosed with prostate cancer during his lifetime. Renowned prostate cancer specialist Sheldon Marks offers the definitive guide for men concerned about or diagnosed with prostate cancer, and for their families.
Since the third edition (2003), there have been significant changes in treatment and resources. Working with Dr. Judd Moul, the Chairman of Urology at Duke and one of the world's top experts on prostate cancer, Marks... View Details
Thrive Don't Only Survive: Dr.Geo's Guide to Living Your Best Life Before & After Prostate Cancer
by Dr. Geo Espinosa (Author)
Prostate cancer is not the end—it’s the beginning. It’s the point where you start taking control.
Information on what to do isn't hard to find. There are dozens of books on prostate cancer, as well as a massive amount of online resources. What's lacking, however, is a trusted, reliable source on implementing the abundance of scientific evidence in a way that’s realistic and sustainable.
Based on his extensive research and clinical experience on natural medicine for prostate problems, Dr. Geo has created a lifestyle blueprint that men can apply immediately to thrive before or... View Details
100 Questions & Answers About Prostate Cancer
by Pamela Ellsworth (Author)
100 Questions & Answers About Prostate Cancer provides authoritative and practical answers to the most common questions asked by patients and their loved ones. Providing both doctor and patient perspectives, this easy-to-read book is a comprehensive guide to the basics of prostate cancer, risk factors and prevention, diagnosis, treatment, survivorship, and life after diagnosis. Written by Dr. Pamela Ellsworth, a prominent urologist and best-selling author, Questions & Answers About Prostate Cancer is an invaluable resource for anyone interested in learning what to expect after being diagnosed... View Details
The Definitive Guide to Prostate Cancer: Everything You Need to Know about Conventional and Integrative Therapies
by Aaron Katz (Author)
The complete guide to coping with prostate cancer, with expert health advice for every man
This comprehensive handbook gives men the vital information they need to effectively navigate every
step of dealing with prostate cancer. A newly diagnosed cancer patient faces a mind-numbing array of treatment options, including medical therapies that carry serious side effects―and determining the right course of action is an overwhelming task. In simple yet scientific terms, this book empowers readers with the tools they need to proactively fight cancer by making the most informed treatment... View Details
The Prostate Health Diet: What to Eat to Prevent and Heal Prostate Problems Including Prostate Cancer, BPH Enlarged Prostate and Prostatitis
by Ronald M Bazar (Author), Coreen Boucher (Editor)
Do you know the best diet for your prostate gland?
Do you know the best diet for preventing or curing prostate cancer?
Do you know the best diet for your prostate health and to prevent prostate disease?
Most men don’t.
The Prostate Health Diet shows you how to find the best diet for you and how to customize your diet for optimum health and your uniqueness.
The Prostate Health Diet is not a fad diet. It will guide you to find what will work for you with practical insights into the often conflicting views of what you should... View Details
PROMOTING WELLNESS for prostate cancer patients
by Mark A. Moyad (Author)
Promoting Wellness for Prostate Cancer Patients is a unique educational book for individuals dealing with the many aspects of prostate cancerfrom prevention to treatment and managing the common (and not so common) side effects of conventional therapy.
In this fully updated and redesigned Fourth Edition, Dr. Moyad covers the latest advancements in prostate cancer treatment while providing his trademark no-nonsense analysis on groundbreaking research that is currently underway. A new series of Quick Tips” run throughout the book, where Dr. Moyad shares his secrets to... View Details